Ergoteles LLC lowered its position in shares of Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Rating) by 45.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,032 shares of the company’s stock after selling 18,868 shares during the quarter. Ergoteles LLC’s holdings in Spruce Biosciences were worth $32,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Bailard Inc. purchased a new position in shares of Spruce Biosciences in the third quarter worth $29,000. Goldman Sachs Group Inc. lifted its holdings in shares of Spruce Biosciences by 39.7% in the second quarter. Goldman Sachs Group Inc. now owns 59,609 shares of the company’s stock worth $104,000 after buying an additional 16,941 shares in the last quarter. Renaissance Technologies LLC increased its position in Spruce Biosciences by 180.7% in the first quarter. Renaissance Technologies LLC now owns 111,700 shares of the company’s stock worth $225,000 after purchasing an additional 71,900 shares during the last quarter. Bank of New York Mellon Corp increased its position in Spruce Biosciences by 317.7% in the first quarter. Bank of New York Mellon Corp now owns 116,501 shares of the company’s stock worth $234,000 after purchasing an additional 88,608 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in Spruce Biosciences in the second quarter worth $331,000. Hedge funds and other institutional investors own 84.21% of the company’s stock.
Spruce Biosciences Trading Up 0.4 %
SPRB stock opened at $2.38 on Friday. The company has a quick ratio of 7.76, a current ratio of 7.76 and a debt-to-equity ratio of 0.05. Spruce Biosciences, Inc. has a twelve month low of $0.95 and a twelve month high of $3.57. The stock has a market capitalization of $56.07 million, a price-to-earnings ratio of -1.27 and a beta of 2.32. The firm’s fifty day simple moving average is $2.49 and its two-hundred day simple moving average is $1.73.
Analyst Ratings Changes
Spruce Biosciences Company Profile
Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial.
- Get a free copy of the StockNews.com research report on Spruce Biosciences (SPRB)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Want to see what other hedge funds are holding SPRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Rating).
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.